Evidence map›Paper›PMID 29334279›Full record

ArticleJournal of drug targeting

Uric acid and the vaccine adjuvant activity of aluminium (oxy)hydroxide nanoparticles.

Sachin G Thakkar, Haiyue Xu, Xu Li, Zhengrong Cui

Open access · greenAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of drug targeting. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Unraveling the enigma: elucidating the relationship between the physicochemical properties of aluminium-based adjuvants and their immunological mechanisms of action.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 2 countries.

Sachin G Thakkara College of Pharmacy, Division of Molecular Pharmaceutics and Drug Delivery , The University of Texas at Austin , Austin , TX , USA.
Haiyue Xua College of Pharmacy, Division of Molecular Pharmaceutics and Drug Delivery , The University of Texas at Austin , Austin , TX , USA.
Xu Lia College of Pharmacy, Division of Molecular Pharmaceutics and Drug Delivery , The University of Texas at Austin , Austin , TX , USA.
Zhengrong Cuia College of Pharmacy, Division of Molecular Pharmaceutics and Drug Delivery , The University of Texas at Austin , Austin , TX , USA.
The University of Texas at Austin · US

Funding

An innovative approach to improve the activity of an aluminum-containing adjuvantR21AI105789 · NIAID · UNIVERSITY OF TEXAS AT AUSTIN · PI CUI, ZHENGRONG · 2013 to 2014
$424k
NIAID NIH HHS R21 AI105789
6 · The paper itself

Abstract

In an effort to improve the adjuvanticity of insoluble aluminium salts, we discovered that the adjuvant activity of aluminium salt nanoparticles is significantly stronger than aluminium salt microparticles, likely related to nanoparticle's stronger ability to directly activate NACHT, LRR and PYD domains-containing protein 3 (NLRP3) inflammasome as the nanoparticles are more efficiently taken up by phagocytic cells. Endogenous signals such as uric acid from cell damage or death caused by the cytotoxicity of aluminium salts are thought to indirectly activate inflammasome, prompting us to hypothesise that the potent adjuvant activity of aluminium salt nanoparticles is also related to their ability to stimulate uric acid production. In the present study, we prepared aluminium (oxy)hydroxide nanoparticles (∼ 30-100 nm) and microparticles (X

Indexed as

NanoparticlesAdjuvants, ImmunologicAluminum HydroxideAnimalsFemaleInflammasomesInjections, IntraperitonealMiceMice, Inbred BALB CNLR Family, Pyrin Domain-Containing 3 ProteinOvalbuminParticle SizeUric AcidVaccinesAdjuvants, ImmunologicAluminum HydroxideInflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinNlrp3 protein, mouseOvalbuminUric AcidVaccinesAluminum hydroxidemicroparticlesnanoparticlesuric acidvaccine adjuvant

Identifiers

PMID29334279
PMCPMC6114149
OpenAlexW2784286507

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.